Clinical application of angiogenic therapy for ischemic heart disease

血管生成治疗缺血性心脏病的临床应用

基本信息

批准号：
10557067
负责人：
FUJITA Masatoshi
金额：
$ 2.18万
依托单位：
KYOTO UNIVERSITY
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (B)
财政年份：
1998
资助国家：
日本
起止时间：
1998 至 1999
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-10557067/
关键词：
Angiogenic therapy bFGF Coronary collateral vessel Effort angina Heparin Counterpulsation Gelatin gel Myocardial ischemia ヘパリン運動療法 LDLアフェレーシス

项目摘要

Angiogenic therapy is noticed as a new treatment for ischemic heart disease, which increases blood flow to the ischemic myocardium as a result of collateral development secondary to the administration of angiogenic growth factors. While the effectiveness of this treatment is reported in several canine experiments, clinical applications have been launched out in Germany and U.S.A..We found that significant coronary collateral development is induced by the implantation of bFGF-impregnated acidic gelatin hydrogel microspheres into the infarct myocardium of dogs with acute coronary occlusion. We also found that regional wall motion abnormality is attenuated by the treatment and this treatment is useful for the preservation of ischemic myocardium. As a future clinical application, we have a plan of angiogenic therapy with use of bFGF-impregnated acidic gelatin hydrogel microspheres for patients who are refractory to medical therapy and are not a candidate for percutaneous or surgical revascularization.EECP (enhanced external counterpulsation) as well as IABP (intra-aortic balloon pumping) increases the aortic diastolic pressure, and decreases the aortic systolic pressure resulting in the augmentation of coronary blood flow and cardiac output. We reported that 35 hours of EECP with the 5,000 U of heparin pretreatment alleviated anginal attack in a patient with effort angina. It is conceivable that EECP combined with heparin pretreatment has great potential as noninvasive treatment of angina patients.

血管生成疗法被认为是缺血性心脏病的一种新疗法，这是由于血管生长生长因子施用继发的附带发育而增加了缺血性心肌的血液。虽然在几个犬类实验中报告了这种治疗的有效性，但在德国和美国已经推出了临床应用。.我们发现，通过植入BFGF浸渍的酸性酸性胶凝胶微球植入急性脊髓核心症状的狗心肌核心。我们还发现，治疗使区域壁运动异常减弱，这种治疗对于保存缺血性心肌有用。作为未来的临床应用，我们使用BFGF浸渍的酸性明胶水凝胶微球的使用计划，用于对医疗治疗难治性并且不是经皮或术语的候选者的候选者（增强的外部抗击）（增强的外部抗击）（增强的外部抗击）（增强的外部抗逆转器），并不是候选的。降低主动脉收缩压，导致冠状动脉血流和心脏输出的增加。我们报告说，有5,000 U的肝素预处理的EECP 35小时缓解了精神锻炼的患者的生气攻击。可以想象的是，EECP与肝素预处理相结合具有无创治疗心绞痛患者的潜力。